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Eﬀ ectiveness of intermittent pneumatic compression in 
reduction of risk of deep vein thrombosis in patients who 
have had a stroke (CLOTS 3): a multicentre randomised 
controlled trial 
CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration* 
Summary 
Background Venous thromboembolism is a common, potentially avoidable cause of death and morbidity in patients 
in hospital, including those with stroke. In surgical patients, intermittent pneumatic compression (IPC) reduces the 
risk of deep vein thrombosis (DVT), but no reliable evidence exists about its eﬀ ectiveness in patients who have had a 
stroke. We assessed the eﬀ ectiveness of IPC to reduce the risk of DVT in patients who have had a stroke.
Methods The CLOTS 3 trial is a multicentre parallel group randomised trial assessing IPC in immobile patients (ie, 
who cannot walk to the toilet without the help of another person) with acute stroke. We enrolled patients from 
day 0 to day 3 of admission and allocated them via a central randomisation system (ratio 1:1) to receive either IPC or 
no IPC. A technician who was masked to treatment allocation did a compression duplex ultrasound (CDU) of both 
legs at 7–10 days and, wherever practical, at 25–30 days after enrolment. Caregivers and patients were not masked to 
treatment assignment. Patients were followed up for 6 months to determine survival and later symptomatic venous 
thromboembolism. The primary outcome was a DVT in the proximal veins detected on a screening CDU or any 
symptomatic DVT in the proximal veins, conﬁ rmed on imaging, within 30 days of randomisation. Patients were 
analysed according to their treatment allocation. Trial registration: ISRCTN93529999. 
Findings Between Dec 8, 2008, and Sept 6, 2012, 2876 patients were enrolled in 94 centres in the UK. The included 
patients were broadly representative of immobile stroke patients admitted to hospital and had a median age of 76 years 
(IQR 67–84). The primary outcome occurred in 122 (8∙5%) of 1438 patients allocated IPC and 174 (12∙1%) of 1438 patients 
allocated no IPC; an absolute reduction in risk of 3∙6% (95% CI 1∙4–5∙8). Excluding the 323 patients who died 
before any primary outcome and 41 without any screening CDU, the adjusted OR for the comparison of 
122 of 1267 patients vs 174 of 1245 patients was 0·65 (95% CI 0·51–0·84; p=0∙001). Deaths in the treatment period 
occurred in 156 (11%) patients allocated IPC and 189 (13%) patients allocated no IPC died within the 30 days of 
treatment period (p=0·057); skin breaks on the legs were reported in 44 (3%) patients allocated IPC and in 20 (1%) patients 
allocated no IPC (p=0∙002); falls with injury were reported in 33 (2%) patients in the IPC group and in 24 (2%) patients 
in the no-IPC group (p=0·221).
Interpretation IPC is an eﬀ ective method of reducing the risk of DVT and possibly improving survival in a wide variety 
of patients who are immobile after stroke. 
Funding National Institute of Health Research (NIHR) Health Technology Assessment (HTA) programme, UK; Chief 
Scientist Oﬃ  ce of Scottish Government; Covidien (MA, USA). 
Introduction
Venous thromboembolism is one of the most important, 
potentially preventable, causes of death and morbidity in 
patients in hospital.1 Although its importance has long 
been recognised in patients undergoing surgery, it is now 
clear that medical patients (sometimes referred to as 
non-surgical patients) also have a high risk of venous 
thromboembolism. Patients who have had a stroke are 
at especially high risk; in prospective studies, venous 
thrombo embolism has been detected in 20–42% of 
patients in hospital who have had a stroke.2–4 Most health-
care systems in developed countries have established 
guidelines promoting routine assessments of risk of 
venous thromboembolism on hospital admission and the 
initiation of prophylaxis in high-risk patients.5–7 Prophyl-
axis with antithrombotic drugs or physical methods, such 
as intermittent pneumatic compression (IPC), reduces 
the risks of deep vein thrombosis (DVT) in patients 
undergoing surgery; but the balance of risk and beneﬁ t 
for these approaches in medical patients is more con-
tentious.5,8,9 After stroke, graduated compression stock-
ings are not eﬀ ective, and the guideline-recom mended 
strategy of selective use of anticoagulants in patients at 
high risk of venous thromboembolism and low risk of 
bleeding is impossible to achieve in practice because of 
the overlap of the factors that predict venous thrombo-
embolism and those pre dicting bleeding risk.3,10 
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IPC includes inﬂ atable sleeves that are wrapped around 
the legs and secured by Velcro (ﬁ gure 1). The sleeves can 
be applied to the calf alone, or the calf and thigh. They 
are inﬂ ated, one side at a time, to compress the legs at 
intervals. Some types inﬂ ate sequentially, ﬁ rst distally, 
then proximally to increase venous ﬂ ow. The frequency 
of inﬂ ation can be ﬁ xed, or in more sophisticated systems 
can be varied depending on the rate of venous reﬁ ll. IPC 
is thought to reduce the risk of venous thrombosis by 
reducing stasis and stimulating release of intrinsic 
ﬁ brinolytic factors.11
IPC has mainly been assessed in patients during, and 
immediately after, surgical operations. A systematic 
review12 identiﬁ ed 22 randomised trials of IPC, which 
included a total of 2779 patients. Use of IPC was 
associated with a 64% reduction in the odds of DVT 
(proximal or calf; p<0·0001).12 This review12 concluded 
that a priority for future research was trials of “prevention 
of venous thromboembolism with mechanical methods 
among high-risk medical patients (such as those with 
stroke)”. A Cochrane review13 of trials of IPC after stroke 
identiﬁ ed only two trials including 177 patients in total,13 
showing IPC was associated with a non-signiﬁ cant 
reduction in risk of DVTs (OR 0∙45, 95% CI 0∙19–1∙10). 
The CLOTS 3 trial therefore aimed to establish whether 
the routine application of IPC to the legs of immobile 
patients who had had a stroke reduced their risk of DVT. 
Methods
Study design and participants
CLOTS 3 trial is a multicentre, parallel group trial that 
took place in 105 hospitals in the UK. The protocol and 
statistical analysis plan have been published previously.14,15 
The full protocol can be viewed online.
To be included in the trial, patients had to be admitted 
to hospital within 3 days of acute stroke and be immobile 
(ie, could not mobilise to the toilet without the help of 
another person). Exclusion criteria included age lower 
than 16 years, subarachnoid haemorrhage, or contra-
indications to IPC such as dermatitis, leg ulcers, severe 
oedema, severe peripheral vascular disease, and con-
gestive cardiac failure.
Patients or a proxy provided written informed consent. 
The protocol was approved by the Scotland A Multicentre 
Research Ethics Committee (08/MREC00/73) & the 
Newcastle & North Tyneside 1 Research Ethics Committee 
for England (08/H0906/137). 
Randomisation and masking
On the day of admission (day 0) or up to day 3, patients 
were randomly assigned (ratio 1:1) to either receive IPC or 
not receive it. The clinician entered the patient’s baseline 
data via a web-based or a 24-h telephone randomisation 
service. After checking the data for completeness and 
consistency, the system generated a treatment allocation. 
We used a minimisation algorithm to achieve optimum 
balance for the following factors: delay since stroke onset 
(day 0 or 1 vs day ≥2 days); stroke severity calculated with a 
validated prognostic model;16 leg weakness (able or not to 
lift both legs oﬀ  the bed); receiving heparin or warfarin at 
enrolment or had received thrombolysis since the stroke. 
Simple minimisation can theoretically lead to alternation 
of treatment allocation, which in this open treatment trial, 
might lead to fore-knowledge of the next treatment to be 
assigned. So, to ensure allocation concealment, our 
system also incorporated a degree of random allocation—
ie, it allocated patients to the treatment group that 
minimised the diﬀ erence between the groups with a 
probability of 0∙8 rather than 1∙0.17 
All patients and investigators were aware of treatment 
allocation, the radiologist or technician doing the CDU 
were masked to treatment group.
Procedures
For patients allocated to the IPC group, we applied the 
Kendall SCDTM express sequential compression system 
(Covidien, MA, USA; ﬁ gure 1), according to the manu-
facturer’s instructions, to both legs. We used thigh-length 
sleeves. This system delivers sequential circum ferential 
compression and incorporates venous reﬁ ll technology so 
that the frequency of compression is tailored to the 
individual patient. We aimed to apply IPC continuously, 
both day and night, (except during washing, physiotherapy, 
or screening compression duplex ultrasound [CDUs]) for 
a minimum of 30 days from randomisation, or until a 
second screening CDU had been done (if after 30 days). 
IPC was discontinued early if the patient: became indepen-
dently mobile, was discharged from the participating 
hospital, declined to continue IPC, had adverse eﬀ ects of 
the IPC that warranted removal. To enhance adherence, 
the manufacturer introduced a modiﬁ ed IPC sleeve, the 
Kendall SCDTM sequential compression “Comfort” sleeves. 
We switched to this new sleeve for the 1197 (42%) patients 
For the study protocol see 
http://www.clotstrial.com
Figure 1: The Kendall SCDTM express sequential compression system (Covidien, MA, USA) with Comfort 
sleeves applied to a patient’s legs
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recruited after Oct 17, 2011. Nursing staﬀ  recorded the 
application of IPC on the medication chart every day to aid 
adherence monitoring. We deﬁ ned perfect adherence (ie, 
100% adherence) as wearing IPC from randomisation 
until the patient regained mobility, was discharged from a 
participating hospital, died, or until 30 days or until a 
delayed second screening CDU. We asked that clinicians 
should not take the patient’s treatment allocation into 
account when deciding whether or not to use anti-
thrombotic drugs after enrolment, to ensure that, as far as 
possible, both treatment groups received the same 
background thromboprophylactic care. 
For the follow-up, we aimed to do a CDU between 
days 7 and 10 and, wherever practical, between 
days 25 and 30 after randomisation, even if the patient had 
been discharged from hospital. The plan not to do the 
second CDU was captured securely before randomisation, 
which might be the case if the patient was likely to be 
discharged home to another region or transferred to a 
rehabilitation facility that did not have facilities to do a 
CDU, and was remote from the randomising centre. We 
allowed researchers to plan not to do a second CDU to 
minimise bias that might arise because of unplanned 
failures to complete a second CDU. We stipulated that; the 
IPC should be removed before the CDU, to mask the 
radiologist or technician to the treatment group; the 
technician should be performing CDU regularly as part of 
a clinical service and the CDU should cover at least the 
popliteal and femoral veins in both legs (ie, visualisation of 
calf veins was not mandatory). The technician completed a 
report form including: whether there was a DVT aﬀ ecting 
femoral, popliteal or calf veins in each leg; whether the calf 
veins were fully visualised; whether the patient arrived 
wearing IPC. We obtained a hard copy of any scans 
reporting a primary outcome for central veriﬁ cation by a 
radiologist (JR). In the absence of a hard copy we obtained 
the local clinical radiology report of the CDU. 
After discharge, or death in hospital, based on a review 
of the medication charts and medical records, the local 
coordinator completed a discharge form that included the 
early secondary outcomes. We sent a postal questionnaire 
to every patient’s general practitioner about 24 weeks after 
enrolment to establish the patient’s vital status, and the 
occurrence of DVTs or pulmonary emboli since hospital 
discharge. We followed up surviving patients at 6 months 
after enrolment by postal questionnaire; in non-
responders, the chief investigator (MD) did a telephone 
interview masked to treatment allocation. 
Statistical analysis
The primary outcome was a symptomatic or asymptomatic 
DVT in the popliteal or femoral (proximal) veins detected 
on a screening CDU or any symptomatic DVT in the 
popliteal or femoral veins, conﬁ rmed on imaging, within 
30 days of randomisation. 
The secondary outcomes within 30 days were: death, 
any DVT (including symptomatic or asymp tomatic calf, 
popliteal or femoral), symptomatic DVT, pulmonary 
embolism conﬁ rmed on imaging or autopsy, compli-
cations of IPC (eg, skin breaks, falls with injury, fractures) 
and adherence. For every patient, we expressed adherence 
as a percentage, which we calcu lated from the number of 
days the IPC was worn (ie, end date minus start date) 
divided by the number of days it should have been worn 
according to our protocol. We did not collect the number 
of hours per day the IPC was worn. 
The secondary outcomes at 6 months were: death from 
any cause and any conﬁ rmed symptomatic or asympto-
matic DVT or pulmonary embolism occurring since 
randomisation. Other secondary outcomes measured at 
6 months included: place of residence; functional status 
and health related quality of life and symptoms of possible 
post phlebitic leg syndrome (eg, leg swelling or ulcers). 
These data will be reported elsewhere as part of a health 
economic analysis.
We originally planned to enrol at least 2000 patients, 
although we prespeciﬁ ed that the trial steering com-
mittee would review this in the light of the overall rate of 
Figure 2: Trial proﬁ le
CDU=compression duplex ultrasound. IPC=intermittent pneumatic compression. *Four patients allocated avoid 
IPC received some IPC: three were transferred to an intensive therapy unit or high dependency unit where IPC was 
standard of care; the other patient received IPC because of miscommunication of the treatment allocation, which 
resulted in 3 days’ treatment with IPC. 
2876 patients randomised
1438 allocated to IPC
14 did not adhere to treatment allocation
1424 adhered to treatment allocation
123 did not complete ﬁrst screening CDU
92 died before any CDU
31 ﬁrst screening CDU missing
5 too ill
23 patient’s refusal
3 administrative or other problem
1315 completed ﬁrst  screening CDU
17 less than 7 days
1091 between 7 and 10 days 
(per protocol)
207 more than 10 days
483 did not complete second screening CDU
127 died
225 second screening CDU not planned
45 previous primary outcome
86 ﬁrst screening CDU missing
12 too ill
61 patient’s refusal
13 administrative or other problem
955 completed second  screening CDU
9 less than 25 days
721 between 25 and 30 days 
(per protocol)
225 more than 30 days
1438 allocated to no IPC
4 did not adhere to treatment allocation
1434 adhered to treatment allocation*
133 did not complete ﬁrst screening CDU
114 died before any CDU
19 ﬁrst screening CDU missing
4 too ill
13 patient’s refusal
2 administrative or other problem
1305 completed ﬁrst  screening CDU  
14 less than 7 days
1060 between 7 and 10 days 
(per protocol)
231 more than 10 days
503 did not complete second screening CDU
163 died
215 second screening CDU not planned
67 previous primary outcome
58 ﬁrst screening CDU missing
6 too ill
36 patient’s refusal
16 administrative or other problem
935 completed second  screening CDU
6 less than 25 days
737 between 25 and 30 days 
(per protocol)
195 more than 30 days
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the primary outcome in both groups combined. This 
aimed to give the trial more than 90% power 
(α 0∙05 [2-sided]) to identify an absolute reduction of risk 
of our primary outcome of 4% (ie, from 10% to 6%). 
On Nov 1, 2010, the frequency of the primary outcome in 
both groups combined among the 581 patients enrolled 
was 12∙2%. The trial steering com mittee, without 
reference to the unblinded data therefore revised the 
sample size to 2800 to ensure that the trial maintained 
power to detect a 4% absolute diﬀ erence in proximal 
DVT (ie, 14% to 10%). The frequency of the primary 
outcome later fell gradually but the trial steering 
committee decided not to reduce the sample size. The 
trial steering committee remained masked to any 
analyses split by treatment group through out the trial. 
The trial statistician (CG) prepared analyses of the 
accumulating data, which the independent data monitor-
ing committee reviewed in strict conﬁ dence at least once 
a year. No explicit stopping rules existed. No other 
members of the trial team, trial steering committee, or 
participants had access to these analyses. Before recruit-
ment was completed, and without input from the trial 
statistician or reference to the unblinded data, the trial 
steering committee prepared a detailed analysis plan 
that was then published.15 For the purposes of all primary 
analyses, we retained participants in the treatment 
group to which they were originally assigned irrespective 
of the treatment they actually received. Inevitably, some 
patients withdrew and were lost to follow-up, and some 
who did return follow-up questionnaires left items 
blank. We excluded these patients from the analyses that 
they had no data for, and we did sensitivity analyses to 
assess the eﬀ ect of these exclusions on the overall 
conclusions. For binary outcomes (eg, occurrence of a 
primary outcome or not), outcomes are presented as 
odds ratios (ORs) and 95% CIs, adjusted using logistic 
regression for the variables in the minimisation 
algorithm. We calcu lated absolute reductions in risk 
from these values. We used Cox proportional hazards 
modelling to analyse the eﬀ ect of treatment on survival 
to 6 months, adjusting for the variables included in our 
minimisation algorithm.
The prespeciﬁ ed subgroup analyses were: the eﬀ ect of 
treatment allocation on the primary outcome subdivided 
by key baseline variables: delay from stroke onset to 
random isation (day 0 or 1 vs day 2 to 7 and day 0 to 2 vs 
3–7); weakness of the legs (able to lift both legs or not); 
stroke severity (with a validated prognostic model);16 risk 
of DVT (high vs low; based on presence or not of risk 
factors at baseline);18 use of heparin, warfarin, or 
thrombolysis at the time of enrol ment; type of stroke 
(conﬁ rmed haemorrhagic vs ischaemic stroke or 
unknown pathological type of stroke); type of 
compression sleeves used (Original vs Comfort). We did 
the subgroup analyses by observing the change in log-
likelihood when the interaction between the treatment 
and the subgroup was added into a logistic regression 
model. We did the statistical analyses using SAS v 9.2 
(SAS Institute Inc, Cary, NC, USA).
The study is registered with http://www.Controlled-
Trials.com, number ISRCTN93529999.
Role of the funding source
The funding organisations, including Covidien, had no 
role in study design, data collection, data analysis, data 
inter pretation, or writing of the report. The corres ponding 
IPC (n=1438) No IPC (n=1438)
Age (years)
Median (IQR)* 76 (67–83) 77 (68–84)
Mean age (SD) 74·2 (12·3) 74·9 (11·9)
Sex
Male 695 (48%) 688 (48%)
Final diagnosis at hospital discharge
Stroke or TIA (deﬁ nite or probably ischaemic) 1211 (84%) 1217 (85%)
Conﬁ rmed haemorrhagic stroke 187 (13%) 189 (13%)
Unknown type 19 (1%) 14 (1%)
Non strokes (included in primary analysis) 19 (1%) 18 (1%)
Missing (no discharge form) 2 (<1%) 0 
Past history and risk factors
Previous deep vein thrombosis or pulmonary embolism 66 (5%) 74 (5%)
Diabetes mellitus 256 (18%) 247 (17%)
Peripheral vascular disease 24 (2%) 31 (2%)
Overweight 417 (29%) 457 (32%)
Current cigarette smoker 250 (17%) 228 (16%)
Independent in daily activities before stroke* 1301 (90%) 1295 (90%)
Lives alone before stroke* 500 (35%) 503 (35%)
Indicators of stroke severity
Able to lift both arms oﬀ  bed* 499 (35%) 502 (35%)
Able to talk and orientated in time, place, and person* 886 (62%) 845 (59%)
Able to lift both legs oﬀ  bed† 494 (34%) 493 (34%)
Able to walk without help* 0 0
Stroke severity—probability of being alive and 
independent in daily activities=0–0·15)†
898 (62%) 892 (62%)
Stroke severity —median (IQR) probability of being alive 
and independent in daily activities 
0·09 (0·02–0·31) 0·09 (0·01–0·31)
On warfarin at recruitment 25 (2%) 29 (2%)
On heparin at recruitment 86 (6%) 78 (5%)
Taken aspirin, dipyridamole, or clopidogrel in past 24 h 
at recruitment
970 (67%) 971 (68%)
Received thrombolysis since admission 249 (17%) 255 (18%)
On heparin or warfarin at recruitment or received 
thrombolysis since admission†
347 (24%) 352 (24%)
Delay 
Delay since stroke onset to randomisation=0–1 days† 624 (43%) 620 (43%)
Delay since stroke onset to randomisation=2 days† 478 (33%) 457 (32%)
Delay since stroke onset to randomisation ≥3 days† 336 (23%) 361 (25%)
Compression duplex ultrasound at 25–30 days deemed 
unlikely to be practical at time of randomisation
225 (16%) 215 (15%)
Data are number of patients (%) unless otherwise stated. IPC=intermittent pneumatic compression. TIA=transient 
ischaemic attack. *Factors included in model to predict probability of being alive and independent at 6 months.16 
†Variables included in minimisation.
Table 1:·Baseline characteristics of patients enrolled into the CLOTS 3 trial (N=2876)
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author had full access to all the data in the study and 
had ﬁ nal responsibility for the decision to submit 
for publication.
Results
Between Dec 8, 2008, and Sept 6, 2012, 2876 patients 
were enrolled in 94 centres in the UK and an additional 
11 centres took responsibility for delivering the allocated 
treatment and follow-up for patients who were 
transferred from the randomising hospital (appendix). 
Of the 2876 patients enrolled, 1438 were randomly 
assigned to receive IPC and 1438 to receive no IPC 
(ﬁ gure 2). The patients’ baseline characteristics were well 
balanced between treatment groups (table 1). Use of 
prophylactic dose heparin or low molecular weight 
(LMWH) after randomisation was very similar between 
treatment groups (table 2). There was a small excess of 
the use of graduated compression stockings in the IPC 
group, perhaps because manufacturers have previously 
recommended using IPC and graduated compression 
stockings in combination.
The mean duration of IPC use was 12∙5 days (SD 10∙9) 
and the median duration was 9 days (IQR 3–22). Perfect 
adherence was achieved in 445 (31%) of 1438 patients in 
the IPC group. The mean adherence was 59∙2% (SD 10∙9) 
and the median adherence was 65∙4% (IQR 20–100).
Table 3 shows patients’ outcomes with respect to our 
primary and secondary outcomes within 30 days of 
enrolment. The primary outcome occurred in 122 (8·5%) 
of 1438 patients allocated to IPC and in 174 (12·1%) of 
1438 patients allocated to no IPC (table 3; OR 0·65 (95% CI 
0·51–0·84; p=0∙001 after adjustment for baseline vari-
ables). The absolute reduction risk (ARR) was 3∙6% 
(95% CI 1∙4–5∙8%). 156 (5%) of 2876 patients attended 
their ﬁ rst or second CDU wearing IPC sleeves, which 
meant that the technician could not be masked for their 
assessment. Our primary outcome was conﬁ rmed in 
276 (93%) of the 296 patients by central review of the 
images (reviewed by JR) and in the remaining 
20 (7%) patients by the local clinical report. To allow for 
any observer bias in detecting symptomatic DVTs not 
detected on routine screening CDU, we repeated the 
primary analysis excluding those primary outcomes where 
a DVT was suspected before the CDU (n=22). The esti-
mates of eﬀ ect were unchanged (data not shown).
We noted signiﬁ cant reductions in the outcome of any 
DVT(symptomatic or asymptomatic involving proximal 
or calf veins) and symptomatic DVT (including proximal 
or calf; table 3). Not all patients had their calf veins 
visualised fully, so in patients with a ﬁ rst CDU, we are 
unable to exclude an isolated calf DVT in 615 (47%) of 
1315 patients in the IPC group and in 596 (46%) of 
1305 patients in the no-IPC group. In those with a second 
CDU, we are unable to exclude an isolated calf DVT in 
453 (47%) of 955 patients in the IPC group and in 
458 (49%) of 938 patients in the non-IPC group. 
Patients allocated to IPC had signiﬁ cantly more skin 
breaks than did patients allocated to no IPC but the risk 
of falls with injury or fractures within 30 days did not 
diﬀ er between groups (table 3). Few of the skins breaks 
or falls with injury were attributed by the local researchers 
to the IPC. Most adverse events either occurred when 
IPC had been removed, or skin breaks aﬀ ected the heels 
(which are not covered by the IPC sleeves) so were 
unlikely to be due to the IPC. However, the reporting of 
secondary outcomes in hospital and adverse eﬀ ects was 
based on case-note review and was not masked to 
treatment allocation. These data for adverse events are 
therefore prone to ascertainment bias. 
We noted non-signiﬁ cantly fewer deaths from all causes 
within 30 days for those allocated IPC (table 3). The Cox 
model adjusted for the factors included in our 
minimisation algorithm showed a reduced probability of 
death for death up to 6 months after randomisation in 
those allocated IPC (ﬁ gure 3). 
We noted no evidence of an excess of venous 
thromboembolism events in the post treatment period 
to indicate that IPC simply deferred venous thrombo-
embolism events (table 4). In our prespeciﬁ ed subgroup 
analyses, we noted no signiﬁ cant interactions in our 
subgroups with the eﬀ ect of treatment on the primary 
outcome (ﬁ gure 4). 
Discussion
The CLOTS 3 trial has shown that IPC (delivering 
sequential circumferential compression via thigh-length 
sleeves at a frequency determined by the venous reﬁ ll 
time) applied to immobile stroke patients, is safe, and 
reduces the risk of proximal DVT (our primary outcome), 
symptomatic DVTs (proximal or calf) and all DVTs 
(symptomatic or asymptomatic, proximal or calf). The 
reduction in symptomatic proximal DVTs was not 
IPC group No IPC group
30-day clinical outcomes and background treatment
Discharge form received (after hospital discharge or death) 1436 (99·9%) 1438 (100%)
Vital status at 30 days known 1432 1431
Post-randomisation prophylactic dose heparin/LMWH prescribed 248 (17%) 240 (17%)
Post-randomisation treatment dose heparin/LMWH prescribed 182 (13%) 219 (15%)
Graduated compression stockings worn 118 (8%) 42 (3%)
Thigh-length stockings only 90 (6%) 22 (2%)
Below-knee graduated compression stockings worn only 17 (1%) 19 (1%)
Both long and short worn 10 (<1%) 1 (<1%)
Unknown length 1 (<1%) 0
6-month clinical outcomes 
Patient or proxy withdrew consent before 6 months 13 (<1%) 7 (<1%)
Missing 6 month follow-up 10 (<1%) 13 (<1%)
No follow-up form because patient dead 330 (23%) 367 (26%)
Follow-up form received 1098 (76%) 1058 (74%)
IPC=intermittent pneumatic compression. LMWH=low-molecular-weight heparin.
Table 2: Patients’ clinical outcomes 
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signiﬁ cant. Although we noted a signiﬁ cant excess of 
skin breaks and a non-signiﬁ cant excess of falls with 
injury, the absolute risks were low and most adverse 
events were not attributed to the IPC. Reassuringly, there 
was a potentially important improvement in survival. 
The CLOTS 3 trial included about the same number of 
patients as had been included in all previous randomised 
trials combined in medical and surgical patients of IPC 
identiﬁ ed by systematic reviews (panel).8,12,13 The 
CLOTS 3 trial focused on prevention and identiﬁ cation 
of proximal DVTs, which are detected more reliably with 
CDU, and are considered clinically more important than 
DVTs restricted to the calf. Calf DVT’s are the most 
frequent component of the cluster of venous 
thromboembolism events used in previous trials of 
venous thromboembolism prophylaxis,8,19 yet their 
detection with CDU is technically challenging and results 
are inconsistent. The patients in CLOTS 3 were enrolled 
by many hospitals in the UK, and had baseline 
characteristics that were similar to the 47% of unselected 
patients with acute stroke admitted to Scottish hospitals 
Figure 3: Cumulative hazard of death during the 6 months after randomisation in the two treatment groups 
IPC=intermittent pneumatic compression. Note that two patients in the IPC arm withdrew very early, did not have 
a date of withdrawal or death and are therefore not included in the baseline number at risk.
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HR 0·86 (0·74–0·99), p=0·042
No-IPC
IPC
IPC 
(n=1438) 
No IPC 
(n=1438)
Absolute risk 
diﬀ erence (95% CI)
Risk ratio (95% CI)* Odds ratio (95% CI) p value
Primary outcome
Primary outcome (proximal DVT) 122 (8·5%) 174 (12·1%) –3·6 (–5·8 to –1·4)
Alive and free of primary outcome 1145 (79·6%) 1071 (74·5%)
Died before any primary outcome 147 (10·2%) 176 (12·2%)
Missing 24 (1·7%) 17 (1·2%)
Unadjusted (dead and missing patients excluded) 122/1267 (9·6%) 174/1245 (14·0%) –4·3 (–6·9 to –1·8) 0·69 (0·55 to 0·86) 0·66 (0·51 to 0·84) 0·001
Primary analysis–adjusted (dead and missing patients excluded) 0·68 (0·54 to 0·85) 0·65 (0·51 to 0·84) 0·001
Unadjusted (dead patients included with DVT and missing 
patients included with no DVT) 
269/1438 (18·7%) 350/1438 (24·3%) –5·6 (–8·6 to –2·6) 0·77 (0·67 to 0·89) 0·71 (0·59 to 0·85) 0·00023
Adjusted (dead patients included with DVT and missing patients 
included with no DVT)
0·75 (0·64 to 0·88) 0·71 (0·60 to 0·86) 0·00021
Secondary outcomes by 30 days or later second compression duplex ultrasound
Dead by 30 days 156 (10·8%) 189 (13·1%) –2·3 (–4·7 to 0·1) 0·82 (0·66 to 1·01) 0·80 (0·63 to 1·01) 0·057
Symptomatic proximal DVT 39 (2·7%) 49 (3·4%) –0·7 (–2·0 to 0·6) 0·79 (0·52 to 1·20) 0·79 (0·51 to 1·21) 0·269
Asymptomatic proximal DVT 83 (5·8%) 125 (8·7%) –2·9 (–4·8 to –1·0) 0·66 (0·50 to 0·87) 0·65 (0·48 to 0·86) 0·003
Symptomatic DVT (proximal or calf) 66 (4·6%) 90 (6·3%) –1·7 (–3·3 to –0·0) 0·73 (0·53 to 0·99) 0·72 (0·52 to 0·99) 0·045
Any DVT (symptomatic or asymptomatic, proximal or calf) 233 (16·2%) 304 (21·1%) –4·9 (–7·8 to –2·1) 0·76 (0·64 to 0·89) 0·72 (0·60 to 0·87) 0·001
All conﬁ rmed pulmonary embolism (imaging or autopsy) 29 (2·0%) 35 (2·4%) –0·4 (–1·5 to 0·7) 0·83 (0·51 to 1·35) 0·83 (0·50 to 1·36) 0·453
Any DVT or conﬁ rmed pulmonary embolism 248 (17·2%) 325 (22·6%) –5·4 (–8·3 to –2·4) 0·75 (0·64 to 0·88) 0·72 (0·59 to 0·86) 0·00035
Any DVT or death 377 (26·2%) 472 (32·8%) –6·6 (–9·9 to –3·3) 0·78 (0·68 to 0·88) 0·72 (0·61 to 0·85) <0·0001
Any DVT, pulmonary embolism, or death 391 (27·2%) 491 (34·1%) –7·0 (–10·3 to –3·6) 0·78 (0·68 to 0·88) 0·72 (0·61 to 0·84) <0·0001
Potential adverse eﬀ ects of IPC
Skin breaks 44 (3·1%) 20 (1·4%) 1·7 (0·6 to 2·7) 2·15 (1·30 to 3·50) 2·23 (1·31 to 3·81) 0·002
Skin breaks attributed to IPC 10 (0·7%) 0 (0·0%) 0·7 (0·3 to 1·1)
Lower limb ischaemia or amputation 0 (0·0) 2 (0·1%) –0·1 (–0·3 to 0·1)
Falls with injury in 30 days 33 (2·3%) 24 (1·7%) 0·6 (–0·4 to 1·6) 1·38 (0·82 to 2·29) 1·39 (0·82 to 2·37) 0·221
Falls with injury in 30 days attributed to IPC 1 (0·1%) 0 (0·0) 0·1 (–0·1 to 0·2)
Fractures within 30 days 4 (0·3%) 4 (0·3%) 0·0 (–0·4 to 0·4)
All odds ratios and risk ratios are adjusted for the variables included in the minimisation algorithm, as speciﬁ ed in the statistical analysis plan, unless otherwise stated. IPC=intermittent pneumatic compression. 
DVT=deep vein thrombosis.*Risk ratios were not prespeciﬁ ed in our statistical analysis plan but are presented to enhance interpretation of results. 
Table 3: Primary and secondary outcomes within 30 days of randomisation
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who were initially immobile (unpublished data from the 
Scottish Stroke Care Audit).20 This suggests that our 
results have external validity and would apply to about 
half of all patients who had had a stroke admitted to 
hospital. Our pre speciﬁ ed decision to increase our 
sample size to take account of the overall primary event 
rate ensured that the trial had adequate power (>90%) to 
detect a 4% absolute diﬀ erence in risk of proximal DVT. 
Central randomisation, mainly masked assessment of 
our primary outcome, low losses to follow-up and 
intention-to-treat analysis have minimised bias. 
The trial has some limitations: moderate adherence to 
IPC; imperfect masking of the technicians (because of 
some patients attending the CDU wearing the IPC, which 
could bias detection of our primary outcome); no masking 
of caregivers (which might bias their use of background 
treatment and assessment of some of the secondary 
outcomes); no masking of patients; some scheduled CDUs 
IPC (n=1438) No IPC (n=1438) Absolute risk 
diﬀ erence (95% CI)
Risk ratio (95% CI)* Odds ratio (95% CI) p value
Dead by 6 months 320 (22·3%) 361 (25·1%) –2·9 (–6·0 to 0·3) 0·87 (0·75 to 1·00) 0·85 (0·70 to 1·01) 0·059
Any DVT 240 (16·7%) 312 (21·7%) –5·0 (–7·9 to –2·1) 0·76 (0·64 to 0·89) 0·72 (0·60 to 0·87) 0·001
Any symptomatic DVT 77 (5·4%) 101 (7·0%) –1·7 (–3·4 to 0·1) 0·76 (0·56 to 1·01) 0·75 (0·55 to 1·02) 0·061
Any conﬁ rmed PE 42 (2·9%) 49 (3·4%) –0·5 (–1·8 to 0·8) 0·86 (0·57 to 1·29) 0·86 (0·56 to 1·30) 0·463
Any death, DVT, or PE 526 (36·6%) 626 (43·5%) –7·0 (–10·5 to –3·4) 0·83 (0·75 to 0·92) 0·74 (0·63 to 0·86) <0·0001
Odds ratios and risk ratios are adjusted for factors included in our minimisation algorithm, as speciﬁ ed in the statistical analysis plan. IPC=intermittent pneumatic compression. 
DVT=deep vein thrombosis. PE=pulmonary embolism. *Risk ratios were not prespeciﬁ ed in our statistical analysis plan but are presented to enhance interpretation of results. 
Table 4: All deaths and venous thromboembolic events (including those in ﬁ rst 30 days) during the 6-month follow-up 
Figure 4: Frequency of the primary outcome by allocated treatment in the prespeciﬁ ed subgroups 
The graph show the point estimates of the OR (adjusted for baseline factors) for every subgroup as a square (whose size is proportional to the amount of 
information) and the horizontal lines depict the 95% CIs. The open diamond indicates the adjusted ORs with 95% CIs for all patients enrolled. The vertical line, at the 
OR of unity corresponds to the line of no eﬀ ect. OR values of less than unity correspond to a reduction in the primary outcome with IPC. p values are for the 
interaction between the treatment eﬀ ect and the subgroup. Patients who died without previous DVT (n=323) and those without either CDU (n=41) are excluded 
from the denominators, which are therefore diﬀ erent to the total number allocated to each treatment group. IPC=intermittent pneumatic compression. DVT=deep 
vein thrombosis. CDU=compression duplex ultrasound. OR=odds ratio. 
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did not include the calf veins and some were missing; and, 
we did not systematically screen for pulmonary emboli. All 
of these might mean we have underestimated the frequency 
of venous thromboembolism. Furthermore, because we 
sys tematically screened for them, many patients found to 
have asymptomatic DVT were then treated with anti-
coagulants to lessen the risk of symptomatic events (DVTs, 
pulmonary emboli, and deaths) occurring. This might bias 
the estimate of the eﬀ ect of IPC. Other potential limitations 
included: lack of central veriﬁ cation of negative scans, use 
of selective source data veriﬁ cation and imbalance in the 
background use of graduated compression stockings but 
we deem these are unlikely to have introduced bias or 
altered the external validity of the results.
The search strategy used in the Cochrane review of 
physical methods for preventing deep vein thrombosis in 
stroke was updated in March 2013.13 Only the two small 
randomised trials included in the original review were 
identiﬁ ed. When the results of CLOTS 3 are incorporated 
the estimates of treatment eﬀ ects are an OR of 0∙66 
(95% CI 0∙52–0∙84) for proximal DVT, an OR of 0∙71 
(0∙59–0∙85) for any DVT and an OR of 0∙81 (0∙65–1∙01) 
for deaths by the end of the treatment period. The two 
other trials did not report any symptomatic DVTs or 
pulmonary emboli.
The reduction in DVT observed in CLOTS 3 is likely to 
be due to the reduced venous stasis and possibly the 
eﬀ ects on intrinsic ﬁ brinolysis observed with IPC.11 The 
improved survival to 6 months observed in those allocated 
IPC is potentially of clinical signiﬁ cance. However, the 
eﬀ ect on survival was not expected, and the CLOTS 3 trial 
had less than 50% power to detect such an eﬀ ect; a trial 
with about 8500 patients would be required to provide 
90% power to detect the observed reduction in all-cause 
mortality. Unfortunately, the autopsy rate was very low, so 
we were unable reliably to assign a cause to most deaths, 
especially given the diﬃ  culty of distin guishing pulmonary 
embolism from other cardio-respira tory problems in 
patients who have had a stroke.21 Selection bias and 
ascertainment biases are unlikely explanations for our 
ﬁ ndings since prognostic factors were balanced at baseline 
and losses to follow-up were extremely low. Therefore, 
taken with the pattern of beneﬁ ts across all the secondary 
outcomes, it seems plausible that the diﬀ erence in survival 
might be real and attributable, at least in part, to IPC. The 
most likely mechanism is a reduction in undiagnosed 
pulmonary embolism that contributed to death.
Previous meta-analyses of trials of heparins/LMWH 
in medical patients, including those with stroke 
(n=36 122 patients) have shown signiﬁ cant reductions in 
pulmonary emboli (three in 1000, 95% CI 1–3), but only 
non-signiﬁ cant reduction in deaths (six in 1000, 0–11), 
perhaps partly because any reduction in major venous 
thromboembolism was oﬀ set by a signiﬁ cant increase in 
major bleeds (four in 1000, 1–7).8,9 By contrast, IPC was 
not associated with an excess of any major adverse eﬀ ects 
that might oﬀ set the beneﬁ ts. The observed eﬀ ect of IPC 
on survival in CLOTS 3 is also reassuring about its safety 
in this high-risk vulnerable population.
CLOTS 3 provides clear evidence that IPC is eﬀ ective 
in reducing the risk of both proximal, symptomatic and 
”any DVT” in immobile patients who have had a stroke. 
Our subgroup analyses suggest that the eﬀ ect is similar 
across a broad range of patients. Importantly, IPC seems 
to be as eﬀ ective in patients with haemorrhagic stroke 
(ﬁ gure 4). Moreover, we have shown that IPC is 
moderately well tolerated and might even improve 
survival after stroke. IPC seems also likely to be eﬀ ective 
in other medical groups of patients at high risk of DVT. 
Panel: Research in context 
Systematic review
In stroke, results from large randomised trials had shown that prophylactic heparin/low 
molecular weight heparin ( LMWH) had no net beneﬁ t and that graduated compression 
stockings did not reduce the risk of DVT. The CLOTS 3 trial aimed to establish whether 
intermittent pneumatic compression (IPC) reduced the risk of deep vein thrombosis (DVT) in 
patients admitted to hospital after an acute stroke who were initially immobile. Before 
starting the trial, we searched for other trials that had addressed this question in stroke 
patients. We updated this search in March, 2013. We searched the Cochrane Stroke Group 
Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL), Medline 
(1966 to March 2013), Embase (1980 to March, 2013), CINAHL (1982 to March, 2013) and 
The British Nursing Index (1985 to March, 2013) using the search terms listed in the 
appendix. We screened reference lists of all relevant papers, searched ongoing trials registers 
(March, 2013), and contacted experts in the ﬁ eld. We included unconfounded randomised 
controlled trials comparing IPC for reducing the risk of DVT with control and in which 
prophylaxis was started within 7 days of the onset of stroke.
We identiﬁ ed two small trials of IPC, one including 151 patients with haemorrhagic stroke 
and the other 26 patients with unspeciﬁ ed stroke. When the results of CLOTS 3 are 
meta-analysed with the results of the two other trials, the estimates of treatment eﬀ ects 
are an OR of 0·66 (95% CI 0·52–0·84) for proximal DVT, an OR of 0·71 (0·59–0·85) for any 
DVT, and an OR of 0·81 (0·65–1·01) for deaths by the end of the treatment period. The 
two other trials did not report any symptomatic DVTs or pulmonary emboli. 
The overall rate of proximal DVT in the CLOTS 3 trial was 10·3% (296 of 2876 patients), 
almost identical to that reported in CLOTS 13 (thigh-length graduated compression 
stockings vs none; 10·3% [259 of 2518 patients]), but higher than that in CLOTS 24 
(thigh-length graduated compression stockings vs below-knee; 7·6% 
[236 of 3114 patients]). The death rates at 30 days were 12·0% (345 of 2876 patients) in 
CLOTS 3, 9·2% (232 of 2518 patients) in CLOTS 2,4 and 11·4% (356 of 3114 patients) in 
CLOTS 1.3 In CLOTS 3, 62·2% (1790 of 2876) of patients enrolled had a probability of a good 
outcome of 0–0·15 (ie, severe stroke; table 1), while the equivalent ﬁ gures were 53·4% 
(1344 of 2518) in CLOTS 13 and 54·3% (1690 of 3114) in CLOTS 2.4 In all three trials, early 
screening CDU was performed in about 91% of enrolled patients, whilst in CLOTS 3 the 
second CDU was done in 65·7% (1890 of 2876) compared with only 57·8% (1456 of 2518) 
in CLOTS 13 and 41·2% (1282 of 3114) in CLOTS 2.4 Since patients in CLOTS 3 had more 
severe strokes, and were more intensively screened for DVT, one would have expected 
higher DVT and death rate—however this may in part have been oﬀ set by 50% of the 
patients in CLOTS 3 receiving eﬀ ective prophylaxis for venous thromboembolism with IPC. 
Interpretation
The CLOTS 3 data provide robust evidence for the eﬀ ectiveness of IPC in the prevention of 
DVT and it possibly improves survival in patients who are initially immobile (ie, cannot walk 
to the toilet without the help of another person) after being hospitalised with acute stroke.
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